UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma

Gynecologic oncology, 2014-09, Vol.134 (3), p.478-485

2014

Volltextzugriff (PDF)

Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2000-01, Vol.18 (1), p.106-115

2000

Volltextzugriff (PDF)

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

The New England journal of medicine, 2023-06, Vol.388 (23), p.2145-2158

2023

Volltextzugriff (PDF)

Combined Intraperitoneal and Intravenous Chemotherapy for Women With Optimally Debulked Ovarian Cancer: Results From an Intergroup Phase II Trial

Journal of clinical oncology, 2003-04, Vol.21 (7), p.1313-1319

2003

Volltextzugriff (PDF)

Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study

Gynecologic oncology, 2020-03, Vol.156 (3), p.523-529

2020

Volltextzugriff (PDF)

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Clinical cancer research, 2020-03, Vol.26 (5), p.1009-1016

2020

Volltextzugriff (PDF)

Prevalence of human papillomavirus genotypes in women from three clinical settings

Journal of medical virology, 2005-01, Vol.75 (1), p.105-113

2005

Volltextzugriff (PDF)

FLORA-5: Front-line chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO] versus chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III double-blind placebo controlled multinational study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS5606-TPS5606

2021

Volltextzugriff (PDF)

Distribution of human papillomavirus type 16 variants in human immunodeficiency virus type 1-positive and -negative women

Journal of general virology, 2004-05, Vol.85 (5), p.1237-1241

2004

Volltextzugriff (PDF)

A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer

Clinical cancer research, 2019-12, Vol.26 (5), p.1009-1016

2019

Volltextzugriff (PDF)

ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial

Obstetrics and gynecology (New York. 1953), 2004-02, Vol.103 (2), p.317-326

2004

Volltextzugriff (PDF)

A randomized phase II study assessing an optimized schedule of oregovomab (O) anti-CA125 vaccination with carboplatin paclitaxel (CP) relative to CP alone in front-line treatment of optimally cytoreduced stage III/IV ovarian cancer (EOC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.5536-5536

2017

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of intraperitoneal topotecan

Investigational new drugs, 1998-01, Vol.16 (2), p.147-153

1998

Volltextzugriff (PDF)

A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube

Gynecologic oncology, 2014-03, Vol.132 (3), p.517-525

2014

Volltextzugriff (PDF)

The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer

Journal of immunotherapy, 2009-01, Vol.32 (1), p.54-65

2009

Volltextzugriff (PDF)

Circadian gating of S phase in human ovarian cancer

Cancer research (Chicago, Ill.), 1987-12, Vol.47 (23), p.6267-6271

1987

Volltextzugriff (PDF)

A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.5012-5012

2012

Volltextzugriff (PDF)

Preventing cervical cancer

Nature medicine, 1996-07, Vol.2 (7), p.749-751

Braly, Patricia

1996

Volltextzugriff (PDF)

Safety and Efficacy of Epoetin Alfa Initiated at 80,000 U Once Weekly in Anemic Cancer Patients Receiving Chemotherapy

Blood, 2004-11, Vol.104 (11), p.4228-4228

2004

Volltextzugriff (PDF)

Introducing evidence-based medicine into a department of obstetrics and gynecology

Obstetrics and gynecology (New York. 1953), 1996-01, Vol.87 (1), p.159-160

1996

Volltextzugriff (PDF)

DNA Content and S-Phase Fraction in Epithelial Ovarian Cancer: What Information Do They Really Add?

Gynecologic oncology, 1998-10, Vol.71 (1), p.1-2

Braly, Patricia

1998

Volltextzugriff (PDF)

Indiana pouch continent urinary reservoir in patients with previous pelvic irradiation

International journal of gynecology and obstetrics, 1990-05, Vol.33 (4), p.385-385

1990

Volltextzugriff (PDF)

A Comparison of Intravenous versus Intraperitoneal Chemotherapy for the Initial Treatment of Ovarian Cancer

Gynecologic oncology, 1994-09, Vol.54 (3), p.338-344

1994

Volltextzugriff (PDF)

A Comparison of Intravenous Versus Intraperitoneal Chemotherapy for the Initial Treatment of Ovarian Cancer

Obstetrical & gynecological survey, 1995-02, Vol.50 (2), p.115-117

1995

Volltextzugriff (PDF)

Flow Cytometry as a Prognostic Factor in Endometrial Cancer—What Does It Add?

Gynecologic oncology, 1995-08, Vol.58 (2), p.145-147

Braly, Patricia S.

1995

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(78)

Sprache

Englisch
(78)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(57)
Science & Technology
(57)
Humans
(50)
Female
(49)
Oncology
(35)
Biological And Medical Sciences
(32)
Medical Sciences
(32)
Middle Aged
(28)
Obstetrics & Gynecology
(28)
Adult
(26)
Aged
(24)
Pharmacology. Drug Treatments
(19)
Antineoplastic Agents
(18)
Chemotherapy
(15)
Ovarian Neoplasms - Drug Therapy
(15)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(14)
Cisplatin - Administration & Dosage
(12)
Gynecology. Andrology. Obstetrics
(10)
Tumors
(10)
Female Genital Diseases
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma

Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Combined Intraperitoneal and Intravenous Chemotherapy for Women With Optimally Debulked Ovarian Cancer: Results From an Intergroup Phase II Trial

Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Prevalence of human papillomavirus genotypes in women from three clinical settings

FLORA-5: Front-line chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO] versus chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III double-blind placebo controlled multinational study

Distribution of human papillomavirus type 16 variants in human immunodeficiency virus type 1-positive and -negative women

A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer

ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial

A randomized phase II study assessing an optimized schedule of oregovomab (O) anti-CA125 vaccination with carboplatin paclitaxel (CP) relative to CP alone in front-line treatment of optimally cytoreduced stage III/IV ovarian cancer (EOC)

Phase I and pharmacokinetic study of intraperitoneal topotecan

A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube

The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer

Circadian gating of S phase in human ovarian cancer

A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162)

Preventing cervical cancer

Safety and Efficacy of Epoetin Alfa Initiated at 80,000 U Once Weekly in Anemic Cancer Patients Receiving Chemotherapy

Introducing evidence-based medicine into a department of obstetrics and gynecology

DNA Content and S-Phase Fraction in Epithelial Ovarian Cancer: What Information Do They Really Add?

Indiana pouch continent urinary reservoir in patients with previous pelvic irradiation

A Comparison of Intravenous versus Intraperitoneal Chemotherapy for the Initial Treatment of Ovarian Cancer

A Comparison of Intravenous Versus Intraperitoneal Chemotherapy for the Initial Treatment of Ovarian Cancer

Flow Cytometry as a Prognostic Factor in Endometrial Cancer—What Does It Add?

Suchergebnisse filtern